SCHEMBL5265385

SCHEMBL5265385

c1cnn(C2(n3cccn3)CCCCCC2)c1

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2A Q12879 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ FBP1 P09467 1/20 0.30
▸ PDE4A P27815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8214992 0.98 GRIN1 (0.32) GRIN1GRIN2AGRIN2BFBP1
SCHEMBL2360547 0.78 — —
SCHEMBL21950524 0.78 GRIN1 (0.33) GRIN1GRIN2AGRIN2BPDE4A
SCHEMBL28852891 0.75 HCAR1 (0.33) PDE4A
SCHEMBL27203400 0.72 TBXAS1 (0.33) —
SCHEMBL15326705 0.71 JAK2 (0.31) —
SCHEMBL21384416 0.71 NOS1 (0.30) —
SCHEMBL11258167 0.70 — —
SCHEMBL30911176 0.70 — —
SCHEMBL15326704 0.70 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478357-B1 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-01-31 — — EP disclosed
US-20050176796-A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2005-08-11 — — US disclosed
EP-1478357-A2 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2004-11-24 — — EP disclosed
WO-2003070236-A2 TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA S.P.A. (IT) 2003-08-28 — — WO disclosed
EP-0276833-B1 Dipyrazoles useful as bronchodilators MERRELL DOW PHARMA (US) 1995-02-15 — — EP disclosed
EP-0276834-B1 Cycloalkane [1,2-c:4,3-c'] dipyrazoles MERRELL DOW PHARMACEUTICALS INC. (US) 1993-06-02 — — EP disclosed
EP-0276833-A2 Dipyrazoles useful as bronchodilators MERRELL DOW PHARMACEUTICALS INC. (US) 1988-08-03 — — EP disclosed
EP-0276834-A1 Cycloalkane [1,2-c:4,3-c'] dipyrazoles MERRELL DOW PHARMACEUTICALS INC. (US) 1988-08-03 — — EP disclosed
US-4734430-A Dipyrazoles and their use as bronchodilators MERRELL DOW PHARMACEUTICALS INC. (US) 1988-03-29 — — US disclosed
US-4734429-A Cycloalkane[1,2-c:4,3-c']dipyrazoles and their use as bronchodilators MERRELL DOW PHARMACEUTICALS INC. (US) 1988-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176796-A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents TP53, NFATC1, MAP3K15 GRIN1 3097/4885GRIN2A 3276/4885GRIN2B 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback